Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Receptor-targeted immunotherapy.

R W Janson, W P Arend

Bulletin on the Rheumatic Diseases

|January 1, 1992

Summary

This summary is machine-generated.

Novel receptor-targeted immunotherapies, including monoclonal antibodies and immunotoxins, show promise for treating human diseases. Further clinical trials are essential to evaluate these advanced genetic engineering techniques, potentially in combination with traditional medications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The role of interleukin-1 receptor antagonist in the prevention and treatment of disease.

Modern rheumatology·2014

Same author

Fate of preformed immune complexes in rabbits and rhesus monkeys.

The Journal of experimental medicine·2009

Same author

Complement activation pathways in murine immune complex-induced arthritis and in C3a and C5a generation in vitro.

Clinical and experimental immunology·2009

Same author

Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody.

Arthritis and rheumatism·2004

Same author

The innate immune system in rheumatoid arthritis.

Arthritis and rheumatism·2001

Same author

May 2001: 32 year old female with dural mass encircling cervical spinal cord.

Brain pathology (Zurich, Switzerland)·2001

Same journal

Getting to the heart of the matter in systemic lupus and rheumatoid arthritis.

Bulletin on the rheumatic diseases·2002

Same journal

The use of low-dose prednisone in the management of rheumatoid arthritis.

Bulletin on the rheumatic diseases·2002

Same journal

Sensible approach to low back pain.

Bulletin on the rheumatic diseases·2002

Same journal

Update on reactive arthritis.

Bulletin on the rheumatic diseases·2002

Same journal

An update on specific COX-2 inhibitors: the COXIBs.

Bulletin on the rheumatic diseases·2002

Same journal

Gout basics.

Bulletin on the rheumatic diseases·2002

See all related articles

Area of Science:

Immunology
Biotechnology
Pharmacology

Background:

Genetic engineering advances have enabled the creation of novel receptor-targeted immunotherapies.
These therapies aim to modulate immune and inflammatory responses for treating various human diseases.

Purpose of the Study:

To review and discuss emerging receptor-targeted immunotherapies developed through modern genetic engineering.
To highlight the potential applications and the need for further clinical evaluation of these novel treatments.

Main Methods:

Review of current literature on receptor-targeted immunotherapies.
Description of specific approaches such as monoclonal antibodies (mAbs) targeting T cell subsets (CD4+, CD5+), immunotoxins, diphtheria toxin-IL-2 conjugates, T cell receptor (TCR) antibodies, IL-1 receptor antagonists, and soluble receptors for IL-1 and TNF.

Related Experiment Videos

Main Results:

Several novel receptor-targeted immunotherapies have been developed using genetic engineering.
These include therapies targeting specific cell surface receptors and cytokines involved in immune and inflammatory processes.

Conclusions:

Emerging receptor-targeted immunotherapies present promising avenues for treating human diseases.
Rigorous clinical evaluation is crucial for these novel approaches, with potential for synergistic effects when combined with conventional anti-inflammatory and immunosuppressive drugs.